ReviewFrontiers in oncology2017
Inflammation in Prostatic Hyperplasia and Carcinoma-Basic Scientific Approach.
Review in Frontiers in oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 73 citations in OpenAlex.
- The gut-prostate axis in benign prostatic hyperplasia: systematic review of microbial dysbiosis and pathogenic mechanisms.BMC urology · 2026Pooled it
- Intervention of Bazi Bushen Capsule on Benign Prostatic Hyperplasia Concomitant with Erectile Dysfunction Induced by Testosterone Supplementation in Spontaneously Hypertensive Rats.Chinese journal of integrative medicine · 2026Article
- Clinical Characteristics of Complex Karyotype Soft Tissue Sarcomas: A Single-Institution Cohort Study.Medicina (Kaunas, Lithuania) · 2026Article
- Benign prostatic hyperplasia to HPIN to carcinoma; the impact of mast cells and VEGF.Diagnostic pathology · 2026Article
- Investigating the impact of gut microbiota-derived metabolites on benign prostatic hyperplasia using network pharmacology approaches.BMC pharmacology & toxicology · 2026Article
- A step forward in enhancing the health-promoting properties of whole tomato as a functional food to lower the impact of non-communicable diseases.Frontiers in nutrition · 2025Review
- Prostate Cancer: Emerging Modifiable Risk Factors and Therapeutic Strategies in the Management of Advanced Cancer.Life (Basel, Switzerland) · 2024Review
- Article
- The Effects of Caloric Restriction on Inflammatory Targets in the Prostates of Aged Rats.International journal of molecular sciences · 2024Article
- Causal associations of immune cells with benign prostatic hyperplasia: insights from a Mendelian randomization study.World journal of urology · 2024Article
- Patterns of B-cell lymphocyte expression changes in pre- and post-malignant prostate tissue are associated with prostate cancer progression.Cancer medicine · 2024Article
- Article
- Phenotype and Reactivity of Lymphocytes Expanded from Benign Prostate Hyperplasic Tissues and Prostate Cancer.Cancers · 2023Article
- The effect of 5-α reductase inhibitor on Th1, Th2, and Th17 cell-related inflammatory response in BPH.World journal of urology · 2023Article
- Research of Prostate Cancer Urinary Diagnostic Biomarkers by Proteomics: The Noteworthy Influence of Inflammation.Diagnostics (Basel, Switzerland) · 2023Article
- Improving Whole Tomato Transformation for Prostate Health: Benign Prostate Hypertrophy as an Exploratory Model.International journal of molecular sciences · 2023Review
- Article
- Article
- Enhancing date seed phenolic bioaccessibility in soft cheese through a dehydrated liposome delivery system and its effect on testosterone-induced benign prostatic hyperplasia in rats.Frontiers in nutrition · 2023Article
- The anti-inflammatory properties of the methanolic extract ofSaudi journal of biological sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic inflammation is associated with both benign conditions and cancer. Likewise, inflammatory cells are quite common in benign prostatic hyperplasia (BPH) and prostatic tissue harboring cancer. Triggers that activate inflammatory pathways in the prostate remain a subject of argument and are likely to be multifactorial, some of these being bacterial antigens, different chemical irritations, and metabolic disorders. Acute and chronic inflammation in prostate leads to accumulation of immunocompetent cells, mainly T lymphocytes and macrophages, but also neutrophils, eosinophils, and mast cells, depending on the type of offending agent. Inflammatory processes activate hyperproliferative programs resulting in nodules seen in BPH, but are also important in creating suitable microenvironment for cancer growth and progression. Inflammatory cells have mostly been shown to have a protumoral effect such as tumor-associated macrophages, but some cell types such as mast cells have antitumoral effects. This review outlines the recent findings and theories supporting the role of inflammatory responses as drivers of both benign and malignant epithelial processes in the prostate gland.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.